NAP1L1 and hepatocellular carcinoma: These data are consistent with the reported data on lung adenocarcinoma, colorectal cancer, and hepatocellular carcinoma (HCC) [8–10], suggesting that NAP1L1 promotes the pathogenesis of breast cancer and might be a potential tumor promoter in breast cancer.